In patients with stable angina pectoris, aminophylline (theophylline ethylenediamine), a nonselective antagonist of adenosine receptors, improves exercise capacity and reduces the severity of exerciseinduced angina.1-4 The most important pharmacological effect of aminophylline, at therapeutic concentrations, is blockade of adenosine receptors. [5] [6] [7] The effects of adenosine are due to the stimulation of two classes of extracellular receptors, subtypes A, and A2.8-10 The stimulation of A1 receptors, present in cardiomyocytes and perivascular sympathetic nerves,11,12 causes electrophysiological effects and inhibits the neuronal release of catecholamines. 13 pectoris (symptom duration ranging from 6 to 48 months), participated in this study. Six patients had suffered a previous myocardial infarction more than 12 months before the study (four non-Q wave myocardial infarction and two inferior). All patients had reproducible positive exercise tests for myocardial ischemia with horizontal or downsloping ST segment depression of 2.0 mm or more and anginal pain. All patients had at least one critical stenosis (internal diameter reduction of more than 70% by visual assessment) in the proximal two thirds of one major epicardial coronary artery. Coronary angiography showed one-vessel disease in 4 patients, two-vessel disease in 12 patients, and threevessel disease in 2 patients. All patients were normotensive, in sinus rhythm, and without evidence of heart failure, cardiomyopathy, or valvular disease. No patient had evidence of left ventricular hypertrophy or conduction defects that could interfere with the interpretation of ST segment changes, and no patient was taking digitalis. All patients gave written informed consent for participation in the study, which was approved by the ethics committee.
Exercise Test
All 18 patients were enrolled. Nitrate preparations other than sublingual nitroglycerin and calcium entryblocking agents were withdrawn 4 days before the study, and 3-blocking agents were withdrawn 5 days before the study. Only sublingual nitroglycerin was used during the latter period, and a minimum of 12 hours were allowed to elapse before testing was begun if this drug was used. Patients were also requested to abstain from xanthinecontaining drugs, food, and drinks for at least 48 hours before the study. Before 20 At the beginning of each exercise test, patients were instructed to promptly report the onset of anginal pain. Immediately after the test, the severity of maximal exercise-induced angina was assessed using a visualanalog scale. 21 The 100-mm scale was marked from no symptom to severe symptom. The scale was measured from 0 to the subject's mark in millimeters. All patients were asked to mark the scale to express the severity of exercise-induced pain and the severity of the anginal pain during daily life for which they used to take nitroglycerin.
Echocardiographic Study
In 12 of the 18 patients (10 men and 2 women), the effects of bamiphylline on left ventricular volumes and function were assessed using two-dimensional echocardiography. After the patient was placed in the left lateral decubitus position, two-dimensional echocardiograms were obtained using a commercially available phased-array imaging system with 2.5-MHz transducers (Hewlett Packard, Sonos 1000). Studies were recorded on VHS videotape. Four views (parasternal long-axis, parasternal short-axis at the mitral, papillary muscle and apical level, apical four-chamber, and two-chamber) were obtained at rest and after administration of bamiphylline or placebo. To this purpose, patients were randomized to two groups of six patients. One group underwent two-dimensional echocardiographic examination 60 to 90 minutes after oral bamiphylline (1200 mg) on day 1 and after placebo on day 2. The other group received placebo on day 1 and bamiphylline on day 2. All studies were performed by one experienced operator blind to the treatment. The echocardiograms were read at baseline and after placebo or bamiphylline administration. The following parameters were analyzed: left ventricular end-diastolic and end-systolic volumes, left ventricular ejection fraction, wall thickening (systolic thickening of the interventricular septum or posterior wall minus diastolic thickening of the interventricular septum or posterior wall/systolic thickening of the interventricular septum or posterior wall) and segmental wall motion. For wall motion analysis, the left ventricle was divided into 11 or circumflex artery were analyzed. Seven stenotic segments were also analyzed. None of the analyzed vessels was filled by angiographically visible collaterals. After intravenous infusion of bamiphylline, the diameters of the normal segments of the proximal and distal third of the coronary artery were similar to those measured at baseline arteriography (3.1±0.5 versus 3.1±0.5 mm and 1.6±0.2 versus 1.7±0.2 mm, respectively; P=NS). Also, the internal diameter of the stenotic segments was not affected by bamiphylline (1.6±0.5 versus 1.6±0.5 mm, P=NS) ( Table 1 ).
Discussion
This study shows that in patients with stable angina pectoris bamiphylline, the most selective antagonist of A1 adenosine receptors available for clinical use increases the ischemic threshold (as reflected by ratepressure product at 1 mm of ST segment depression), prolongs the exercise duration, delays the onset of anginal pain, and reduces the severity of angina for a similar degree of ST segment depression. The improvement of the exercise capacity and of the anginal pain obtained with bamiphylline is comparable with that reported with aminophylline,1-4 a nonselective antagonist of adenosine receptors. These findings indicate that both the anti-ischemic and the antianginal actions of aminophylline are, at least partially, mediated by inhibition of A, adenosine receptors.
Bamiphylline, a 7,8-bisubstituted of aminophylline, has been successfully used to treat bronchial asthma and lung anaphylaxis in young children and infants24 and chronic obstructive pulmonary disease in adults with an efficacy comparable to that of aminophylline but with substantially fewer side effects.25,26 The therapeutic threshold of bamiphylline is almost 50 times lower than that of aminophylline (0.2 ,ug/mL versus 10 ,ug/mL), whereas the tolerance range is almost 100 times wider.27," In crude synaptic membranes prepared from rat brain, bamiphylline displaces radioligands from A, adenosine receptors with a potency similar to that of 8-phenil-theophylline, whereas it showed a much lower potency on A2 adenosine receptors. This resulted in a high degree of A1 receptor selectivity indicated by a A2/A1 Ki ratio of 596.19 A critical issue in our study was the choice of an appropriate dose of bamiphylline. In vitro studies have shown that bamiphylline, at the mean plasma concentration obtained in the present study (-0.5. 10-M), displaces 80% of 3H-DPX (an antagonist of A1 adenosine receptors), 50% of 3H-CHA (an agonist of A1 adenosine receptors), but 5% only of 3H-NECA (an agonist of A2 adenosine receptors). Thus, at the dose used in this study, bamiphylline administration resulted in a rather selective blockade of A1 adenosine receptors.
Anti-Ischemic Effects of Bamiphylline
The mechanism of the anti-ischemic effect of bamiphylline does not appear to be mediated by coronary artery dilation. In fact, in this study, intravenous administration of bamiphylline had no significant effect on the luminal diameter of normal or stenotic segments of large epicardial coronary arteries. Furthermore, the anti-ischemic action of bamiphylline does not seem to be related to a reduction of myocardial oxygen consumption. Indeed Feigl, 38 thetic coronary vasoconstriction during exercise might improve subendocardial perfusion through a selective constriction of subepicardial vessels. The hypothesis that the vasoconstrictor effect of methylxanthines involves catecholamines is supported by the observation that the increase of vascular resistance caused by aminophylline in the conscious dog is attenuated by a-adrenergic blockade. 39 Of note, in our study, bamiphylline did not affect heart rate or arterial blood pressure under resting conditions, suggesting that prejunctional A1 adenosine receptors are not active at rest. Another potential mechanism by which bamiphylline can limit subepicardial perfusion might be inhibition of ATP-sensitive potassium channels. In fact, recent preliminary data suggest that the activation of these channels that provokes coronary vasodilation is due, in part, to the activation of A, adenosine receptors. 40 Effects of Bamiphylline on the Anginal Pain In our study, the improvement of exercise-induced anginal pain obtained with bamiphylline was greater than that predicted on the basis of the improvement of myocardial ischemia. Indeed, the severity of pain at peak exercise normalized for maximal ST segment depression was significantly less after bamiphylline than after placebo. These findings suggest that the improvement of the anginal pain produced by bamiphylline is likely to be due also to the direct inhibition of the algogenic effects of adenosine. Adenosine is a mediator of the ischemic pain,41'42 and its algogenic effects are, at least partially, mediated by A, receptors. 43'44 Preliminary observations demonstrated that bamiphylline significantly reduces the pain produced by intra-arterial infusion of adenosine43 and that the intradermal preinjection of bamiphylline in healthy volunteers completely prevents the pain induced by intradermal injection of adenosine. 44 The present study supports and expands these previous observations, suggesting also that the algogenic effects caused by endogenous adenosine released during exerciseinduced myocardial ischemia are partially mediated by A, adenosine receptors. However, the observation that the degree of ST segment depression at the onset of pain was not affected by bamiphylline indicates that other algogenic substances are involved in the genesis of the anginal pain. Study Limitations be mediated by vascular A2 receptors suggests that the A1 receptors selectivity of bamiphylline is substantially preserved in humans. 44 Finally, the lack of significant vasoactive effects of bamiphylline on coronary stenosis diameter found at rest during diagnostic catheterization does not exclude the possibility of vasoactive effects during exercise.
Conclusions
In conclusion, in patients with stable angina pectoris, oral administration of bamiphylline, a rather selective antagonist of A1 adenosine receptors, increases the ischemic threshold, prolongs the exercise duration, delays the onset of anginal pain, and reduces its severity for a similar degree of ST segment depression. The anti-ischemic action of bamiphylline is not mediated by a reduction of myocardial oxygen consumption, left ventricular unloading, or coronary stenosis dilation, but it is probably due to redistribution of coronary blood flow toward the subendocardium. The antianginal action of bamiphylline appears to be due also to direct blockade of cardiac sensory receptors sensitive to adenosine. Finally, the results of our study indicate that both the anti-ischemic and the antianginal action of aminophylline, a nonselective adenosine antagonist, observed in earlier studies are partially mediated by the inhibition of A1 receptors. Because of the lack of cardiostimulant effects and the absence of major undesirable side effects, bamiphylline more than aminophylline might represent a complementary drug in the treatment of patients with coronary artery disease.
